Parkinson's disease: Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study

Research output: Contribution to journalArticle

Standard

Parkinson's disease : Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study. / Lerche, Stefanie; Wurster, Isabel; Röben, Benjamin; Machetanz, Gerrit; Zimmermann, Milan; Bernhard, Felix; Stransky, Elke; Deuschle, Christian; Schulte, Claudia; Hansson, Oskar; Zetterberg, Henrik; Gasser, Thomas; Berg, Daniela; Maetzler, Walter; Brockmann, Kathrin.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, No. 2, 2019, p. 165-170.

Research output: Contribution to journalArticle

Harvard

Lerche, S, Wurster, I, Röben, B, Machetanz, G, Zimmermann, M, Bernhard, F, Stransky, E, Deuschle, C, Schulte, C, Hansson, O, Zetterberg, H, Gasser, T, Berg, D, Maetzler, W & Brockmann, K 2019, 'Parkinson's disease: Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study', Journal of Neurology, Neurosurgery and Psychiatry, vol. 90, no. 2, pp. 165-170. https://doi.org/10.1136/jnnp-2018-318956

APA

CBE

Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K. 2019. Parkinson's disease: Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry. 90(2):165-170. https://doi.org/10.1136/jnnp-2018-318956

MLA

Vancouver

Author

Lerche, Stefanie ; Wurster, Isabel ; Röben, Benjamin ; Machetanz, Gerrit ; Zimmermann, Milan ; Bernhard, Felix ; Stransky, Elke ; Deuschle, Christian ; Schulte, Claudia ; Hansson, Oskar ; Zetterberg, Henrik ; Gasser, Thomas ; Berg, Daniela ; Maetzler, Walter ; Brockmann, Kathrin. / Parkinson's disease : Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study. In: Journal of Neurology, Neurosurgery and Psychiatry. 2019 ; Vol. 90, No. 2. pp. 165-170.

RIS

TY - JOUR

T1 - Parkinson's disease

T2 - Journal of Neurology, Neurosurgery and Psychiatry

AU - Lerche, Stefanie

AU - Wurster, Isabel

AU - Röben, Benjamin

AU - Machetanz, Gerrit

AU - Zimmermann, Milan

AU - Bernhard, Felix

AU - Stransky, Elke

AU - Deuschle, Christian

AU - Schulte, Claudia

AU - Hansson, Oskar

AU - Zetterberg, Henrik

AU - Gasser, Thomas

AU - Berg, Daniela

AU - Maetzler, Walter

AU - Brockmann, Kathrin

PY - 2019

Y1 - 2019

N2 - Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ1-42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven per cent of the patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ1-42 levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ1-42 levels at baseline developed cognitive impairment more frequently and earlier during follow-up. Conclusion: We conclude that in patients with sporadic PD, low levels of Aβ1-42 are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.

AB - Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ1-42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven per cent of the patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ1-42 levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ1-42 levels at baseline developed cognitive impairment more frequently and earlier during follow-up. Conclusion: We conclude that in patients with sporadic PD, low levels of Aβ1-42 are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.

KW - amyloid-beta

KW - CSF

KW - longitudinal

KW - Parkinson

U2 - 10.1136/jnnp-2018-318956

DO - 10.1136/jnnp-2018-318956

M3 - Article

VL - 90

SP - 165

EP - 170

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 1468-330X

IS - 2

ER -